肺癌抗原标志物联合检测的临床应用  

Clinical application of joint detection with lung cancer antigen markers

作　　者：温仁祝[1] 戴磊[1] 张亚男[1] 

机构地区：[1]广西医科大学第一附属医院胸外科,广西南宁530021

出　　处：《蛇志》2015年第2期118-120,共3页Journal of Snake

基　　金：广西区卫生厅自筹项目(桂卫自筹Z2014047)

摘　　要：目的探讨肺癌抗原标志物联合检测的最佳组合。方法随机抽取200例确诊为原发性肺癌的患者,测定患者血液中多种肿瘤抗原标志物的水平,并进行统计学分析。结果检测的多项肿瘤标志物中CEA、NSE、CYFRA21-1和CA125的阳性率相对较高;血清各标志物的表达与临床分期有关。结论联合检测CEA、NSE、CYFRA21-1和CA125能提高肺癌患者的临床诊断准确率。Objective To explore the best combination of joint detection with lung cancer antigen markers.Methods A random sample of 200 patients diagnosed with primary lung cancer patients,measuring the level of a wide variety of tumor antigen markers in the blood and statistical analysis. Results In the detection of multiple tumor markers CEA,NSE,CYFRA21-1and CA125 positive rate is relatively high;serum markers in the expression of related to clinical stage. Conclusion The combined detection of CEA and CA125,NSE,CYFRA21-1can improve the accuracy of clinical diagnosis of lung cancer patients.

关 键 词：肺癌 肿瘤抗原标志物 联合检测 

分 类 号：R734.2[医药卫生—肿瘤]